LexisNexis’ Post

AI is poised to make a major impact on the life sciences industry. And regulatory oversight of AI use will, too. Follow critical FDA administrative activity with the FDA Artificial Intelligence (AI) Regulatory Activity Tracker in Practical Guidance Life Sciences. https://bit.ly/4eY3DB6

Register for our Webinar: AI & CDS Regulatory History and FDA Tools, Thursday May 30th at 1pm EST to learn about evolution of regulatory pathways for Clinical Decision Support tools, and their newer, AI-enabled descendants. #triageGO

Currently, more than 850 artificial intelligence enabled products have received FDA-authorization, yet recent cultural noise surrounding AI has caused controversy and unease. Register for our Webinar: AI & CDS Regulatory History and FDA Tools, Thursday May 30th at 1pm EST to learn about evolution of regulatory pathways for Clinical Decision Support tools, and their newer, AI-enabled descendants.

Are you curious about how the FDA is regulating AI tools? We are frequently asked this when talking about our solutions, and we see a lot of confusion on the topic, especially when it comes to startups or companies new to the medical field. We are committed to not only deliver clinically proven solutions, but also to do so while being 100% compliant with FDA guidelines. Listen in to find out more!

The #AIAct was published in the EU Official Journal today so this regulatory train has now officially left the station and the implementation deadlines countdown has now started. Pro tip for #medicaldevices and #invitrodiagnostics manufacturers: don't be unprepared like Claude (although Claude does realize its importance), but be prepared. This regulation will seriously move goalposts for any #medicaldevice company that has devices that incorporate an AI system or are software comprising an AI system. Contact us for help! #artificialintelligence #AI #medtech #EUMDR #EUIVDR #genetictesting #moleculardiagnostics #SaMD https://lnkd.in/e96TaPcE

While generative artificial intelligence (AI) (gen AI) has much promise, the global AI regulatory environment could pose challenges for the life sciences industry. Clarity in the regulatory environment can help accelerate the AI journey and adoption across regions. Explore the regulatory environment of AI in six geographical jurisdictions #DeloitteGreece #impactthatmatters #pharma #GenAI #regulation https://lnkd.in/dBf27sbH

According to a new research report "AI report 2023" published by intellectual property firm Marks & Clerk, only 12 EPO patent applications were filed in the field of drug discovery in 2022. This result is completely unbelievable. According to the report, the number of AI-based patents filed in the medical field will be 2,771 in 2022, a fourfold increase from 2018. Incredibly, looking at the subsector, the number of applications for the use of AI in drug discovery continues to decline, reaching only 12 applications in 2022. Rather than interpreting this as a lack of new inventions or a shift in research and development trends, maybe the true explanation relates to long-term strategy, with inventors instead choosing to use patents to protect the fruits of their drug discovery platforms, whilst keeping the algorithms confidential. https://lnkd.in/ejAJHjei #drugdiscovery #AI

🔬 Exploring Generative AI Regulations in Life Sciences 🔬 Generative artificial intelligence (GenAI) holds immense promise for revolutionizing the life sciences sector. However, navigating the global regulatory landscape presents challenges that demand attention. Clarity in regulatory frameworks is crucial to accelerating the AI journey and fostering widespread adoption across regions. In a recent study, we delved into the regulatory environments of AI across six key geographical jurisdictions. Understanding these regulations is vital for companies aiming to leverage GenAI effectively while ensuring compliance and ethical use. #GenerativeAI #LifeSciences #AIRegulations #RegulatoryCompliance #EthicalAI #Innovation #GlobalAI #DigitalHealth #Healthcare #BioTech #Pharma

The EU AI Act is here, setting a global precedent for hashtag#AI governance. This comprehensive regulation aims to make AI systems safe, transparent, and fair. What does this mean for the hashtag#medicaldevice sector? Our latest article analyses the implications and highlights the key challenges medical device manufacturers face under the AI Act. 📰 Learn more about navigating these new regulations in health care: https://lnkd.in/ezMwnaqf

Last week, we had a great webinar about Artificial Intelligence in french. Don't miss the opportunity to attend the same webinar in English to learn more about Artificial Intelligence. The webinar is presented by Thomas LOMMATZSCH, director BU Medical of AFNOR at 5.00 pm CET today. Artificial Intelligence (AI) is a topic we are talking about more and more and this has an impact on the medical device sector. So, it is important to be prepared as a PRRC and also to be familiar with the EU AI Act if you work for a manufacturer that includes AI in its devices. The webinar is open to all and free of charge. To register for the session in English on March 26th at 5.00 pm CET, click here: https://lnkd.in/ewXs2uhQ We look forward to seeing you. #MDR #IVDR #EUAIAct #ArtificialIntelligence #PRRC #medicaldevice #regulation #regulatoryaffairs #quality #europe